Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT07012980
Phase
PHASE2
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Glofitamab
  • Polatuzumab Vedotin
  • Zanubrutinib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects will only be included in the study if they meet all the following criteria:
  • Written informed consent.
  • Aged 70 years old or above.
  • ECOG performance status of 0-3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →